Advance Search
ZHU Shichun, TANG Ruze. Impact of radiotherapy on prognosis of children with high-risk neuroblastoma[J]. Journal of Clinical Medicine in Practice, 2023, 27(13): 16-19, 25. DOI: 10.7619/jcmp.20231480
Citation: ZHU Shichun, TANG Ruze. Impact of radiotherapy on prognosis of children with high-risk neuroblastoma[J]. Journal of Clinical Medicine in Practice, 2023, 27(13): 16-19, 25. DOI: 10.7619/jcmp.20231480
shu

Impact of radiotherapy on prognosis of children with high-risk neuroblastoma

  • 1.

    Department of Pediatric Surgery, the Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu, 225000

  • 2.

    Department of General Surgery, the Affiliated Children′s Hospital of Soochow University, Suzhou, Jiangsu, 215000

More Information
  • Received Date: May 08, 2023
  • Revised Date: June 20, 2023
  • Available Online: July 18, 2023
    Graphical Abstract
    • Abstract
  • Objective 

    To analyze the effect of radiotherapy on the prognosis of pediatric high-risk neuroblastoma (NB).

    Methods 

    The clinical data of 100 cases of high-risk NB were retrospectively analyzed. The influencing factors affecting NB recurrence and survival were assessed through single factor analysis. The recurrence-free survival and overall survival of NB in radiotherapy group and non-radiotherapy group were analyzed by Kaplan-Meier method. The recurrence-free survival rate and overall survival rate of NB were compared by Log-rank.

    Results 

    Of 100 children with NB, 34 recurred, 66 did not relapse, 74 survived, and 26 died. Univariate analysis showed that age, distant tumor metastasis and radiotherapy were influencing factors of tumor recurrence in NB children(P < 0.05), while age, distant tumor metastasis, and MYCN gene amplification were influencing factors of survival of NB children (P < 0.05). The results of survival analysis showed that there was statistically significant difference in relapse-free survival rate between the radiotherapy group and the non-radiotherapy group (P < 0.05), but there was no statistically significant difference in overall survival rate between the two groups (P>0.05).

    Conclusion 

    Age, distant tumor metastasis, and radiotherapy are risk factors for NB recurrence, while age, distant tumor metastasis, and MYCN gene amplification are influencing factors for NB survival. Radiotherapy can improve the recurrence-free survival rate of children with high-risk NB, but it has no significant effect on the overall survival rate.

    • FullText(HTML)
    • References (18)
  • [1]
    AMBROS I M, TONINI G P, PÖTSCHGER U, et al. Age dependency of the prognostic impact of tumor genomics in localized resectable MYCN-nonamplified neuroblastomas. report from the SIOPEN biology group on the LNESG trials and a COG validation group[J]. J Clin Oncol, 2020, 38(31): 3685-3697. doi: 10.1200/JCO.18.02132
    [2]
    TAKITA J. Molecular basis and clinical features of neuroblastoma[J]. JMA J, 2021, 4(4): 321-331.
    [3]
    张婷, 李艳华, 李珊珊, 等. 单中心儿童神经母细胞瘤4期患者临床疗效及预后分析[J]. 中国小儿血液与肿瘤杂志, 2020, 25(3): 153-158. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXY202003007.htm
    [4]
    孙晓非, 甄子俊, 王娟, 等. 483例神经母细胞瘤基于危险因素分层治疗结果分析[J]. 中华小儿外科杂志, 2022, 43(3): 193-200. doi: 10.3760/cma.j.cn421158-20200530-00384
    [5]
    CHUNG C, BOTERBERG T, LUCAS J, et al. Neuroblastoma[J]. Pediatr Blood Cancer, 2021, 68(Suppl 2): e28473.
    [6]
    ARUMUGAM S, MANNING-CORK N J, GAINS J E, et al. The evidence for external beam radiotherapy in high-risk neuroblastoma of childhood: a systematic review[J]. Clin Oncol, 2019, 31(3): 182-190. doi: 10.1016/j.clon.2018.11.031
    [7]
    中国抗癌协会小儿肿瘤专业委员会, 中华医学会小儿外科学分会肿瘤学组, 赵强, 等. 儿童神经母细胞瘤诊疗专家共识CCCG-NB-2021方案[J]. 中华小儿外科杂志, 2022, 43(7): 588-598. doi: 10.3760/cma.j.cn421158-20211227-00638
    [8]
    BRAUNSTEIN S E, LONDON W B, KREISSMAN S G, et al. Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: a report from the COG A3973 study[J]. Pediatr Blood Cancer, 2019, 66(7): e27736. doi: 10.1002/pbc.27736
    [9]
    夏剑锋, 张倩, 梅海. 儿童神经母细胞瘤临床诊疗的研究进展[J]. 医学综述, 2020, 26(4): 690-694. doi: 10.3969/j.issn.1006-2084.2020.04.013
    [10]
    陈吉, 黄磊, 易军. 神经母细胞瘤分子治疗研究进展[J]. 中华小儿外科杂志, 2018, 39(5): 397-400. doi: 10.3760/cma.j.issn.0253-3006.2018.05.016
    [11]
    刘涛, 盛庆丰, 刘江斌, 等. INSS 4期神经母细胞瘤患儿3年无事件生存率的相关因素分析[J]. 临床小儿外科杂志, 2022, 21(2): 121-127. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXR202202005.htm
    [12]
    RITENOUR L E, RANDALL M P, BOSSE K R, et al. Correction to: genetic susceptibility to neuroblastoma: current knowledge and future directions[J]. Cell Tissue Res, 2021, 383(2): 905. doi: 10.1007/s00441-020-03277-8
    [13]
    梁伟玲, 叶小帆, 钟共, 等. 儿童4期神经母细胞瘤联合治疗的临床疗效观察[J]. 中国当代儿科杂志, 2022, 24(7): 759-764. https://www.cnki.com.cn/Article/CJFDTOTAL-DDKZ202207007.htm
    [14]
    朱呈光, 贺湘玲, 汤止戈, 等. 44例儿童神经母细胞瘤临床分析[J]. 中国当代儿科杂志, 2020, 22(11): 1193-1197. https://www.cnki.com.cn/Article/CJFDTOTAL-DDKZ202011011.htm
    [15]
    MACFARLAND S, BAGATELL R. Advances in neuroblastoma therapy[J]. Curr Opin Pediatr, 2019, 31(1): 14-20. doi: 10.1097/MOP.0000000000000711
    [16]
    周珺珺, 赵洁, 汤静燕, 等. Ⅲ~Ⅳ期神经母细胞瘤患儿放射治疗预后因素分析[J]. 上海交通大学学报: 医学版, 2021, 41(8): 1051-1055. https://www.cnki.com.cn/Article/CJFDTOTAL-SHEY202108009.htm
    [17]
    ZHAO Q, LIU Y, ZHANG Y Y, et al. Role and toxicity of radiation therapy in neuroblastoma patients: a literature review[J]. Crit Rev Oncol Hematol, 2020, 149: 102924.
    [18]
    汤止戈, 陈可可, 邓坦, 等. 24例儿童高危神经母细胞瘤调强适形放疗的近期疗效分析[J]. 中国当代儿科杂志, 2021, 23(6): 621-625. https://www.cnki.com.cn/Article/CJFDTOTAL-DDKZ202106013.htm
    • Related Articles

  • Cited by

    Periodical cited type(16)

    1. 张磊. 达格列净在NAFLD并CHF患者中的应用效果及可能机制. 新疆医学. 2025(01): 68-72 .
    2. 刘凯，陈园园，陈海燕，项学军，乔锐，聂佩. 达格列净对急性心肌梗死合并糖尿病患者经皮冠状动脉介入治疗后糖代谢和心功能的影响. 西北药学杂志. 2024(03): 189-193 .
    3. 刘雪龙，侯卫东，田勇. 二甲双胍联合贝那鲁肽对T2DM患者糖脂代谢及SCGN、Asprosin水平的影响. 中国卫生工程学. 2024(03): 413-416 .
    4. 周颢，罗英杰. 达格列净联合二甲双胍对肥胖2型糖尿病患者糖脂代谢和微炎症状态的影响. 中国民康医学. 2023(08): 138-141 .
    5. 骆景耀，胡义阳. 达格列净治疗2型糖尿病的临床效果及对脂代谢和内脏脂肪的影响. 临床合理用药. 2023(20): 31-33+37 .
    6. 张武健，沓世泽，黄东柱. 达格列净对血糖控制不佳的2型糖尿病患者肾脏保护作用的研究. 糖尿病新世界. 2023(10): 10-13 .
    7. 秦会娟，侯程浩，张茂杰. 达格列净联合二甲双胍缓释片治疗糖尿病合并慢阻肺稳定期患者的效果分析. 糖尿病新世界. 2023(11): 91-94 .
    8. 沈志伟，陈军童，王黎亚. 空腹血糖结合β_2-微球蛋白对糖尿病患者肾功能损伤的诊断效能评价. 中国临床医生杂志. 2023(08): 922-924 .
    9. 王丽，苏钢，洪娟，宣小明. 达格列净对早期糖尿病肾病的疗效观察. 中国医师进修杂志. 2023(10): 930-933 .
    10. 郑良宏，郑新元. SGLT2抑制剂在2型糖尿病患者治疗中的应用. 糖尿病新世界. 2023(21): 107-109+113 .
    11. 王晶，刘易婷，刘哲. 替米沙坦联合瑞舒伐他汀治疗糖尿病合并冠心病对患者外周胰岛素抵抗、糖化血红蛋白、脂蛋白和心肌缺血的影响. 陕西医学杂志. 2022(05): 595-598 .
    12. 李枫. 观察达格列净对血糖控制不达标的超重和肥胖2型糖尿病患者血糖控制效果及BMI和肾功能的影响. 糖尿病新世界. 2022(14): 85-88 .
    13. 徐爽，童慧昕，梁琳琅，孔媛. 二甲双胍、达格列净、利拉鲁肽联合治疗新诊断超重或肥胖2型糖尿病患者临床疗效及安全性. 临床军医杂志. 2022(12): 1252-1254+1257 .
    14. 战玲，宋杰，杨姗姗. 达格列净联合福辛普利治疗高血压合并糖尿病的效果分析. 中国校医. 2022(12): 948-951 .
    15. 郑伟. 达格列净或沙格列汀联合二甲双胍治疗2型糖尿病的临床疗效探讨. 糖尿病新世界. 2021(15): 89-92 .
    16. 林金城. 达格列净对2型糖尿病合并高尿酸血症患者血糖及尿酸的影响. 医学理论与实践. 2021(24): 4270-4272 .

    Other cited types(2)

Catalog

    Get Citation
    PDF
    XML
    Article views (142) PDF downloads (10) Cited by(18)
    Turn off MathJax
    Article Contents
    Abstract
    References

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return